Peer-reviewed veterinary case report
Immunomodulators tested for treating inflammatory bowel disease
By Rychlik, Andrzej et al.·Published in Acta veterinaria Hungarica·2013·University of Warmia and Mazury in Olsztyn Department of Clinical Diagnostics·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effectiveness of natural and synthetic immunomodulators in the treatment of inflammatory bowel disease in dogs.
- Species:
- dog
Plain-English summary
A group of 28 dogs with inflammatory bowel disease (IBD) were treated with a special diet containing natural and synthetic immunomodulators for 42 days. The treatment included a specific ingredient called β-1,3/1,6-D-glucan, which showed the best results by quickly reducing symptoms and improving overall health. Dogs treated with this ingredient had lower disease activity scores and longer periods without symptoms compared to those receiving other treatments like HMB and levamisole. Overall, β-1,3/1,6-D-glucan proved to be an effective option for managing IBD in dogs.
People also search for: dog inflammatory bowel disease treatment · IBD diet for dogs · natural remedies for dog gut health
Abstract
The aim of the study was to evaluate the usefulness of immunomodulators in the treatment of inflammatory bowel disease (IBD) in dogs. Twenty-eight dogs diagnosed with IBD took part in the study. The animals received a food containing extruded immunomodulators: β-1,3/1,6-D-glucan, β-hydroxy-β-methyl-butyrate (HMB) and levamisole for 42 days. Whole blood samples were analysed before and after therapy assessing changes in phagocyte activity (respiratory burst activity, RBA and potential killing activity, PKA), evaluation of proliferation response of mitogen-stimulated lymphocytes and serum gamma globulin levels, lysozyme activity, ceruloplasmin levels and interleukin activity (IL-6 and IL-10). In this experiment, β-1,3/1,6-D-glucan delivered the highest level of treatment efficacy by producing the quickest therapeutic effect, lowering Canine Inflammatory Bowel Disease Activity Index (CIBDAI) values to below 3, improving histopathological parameters, decreasing IL-6 levels, increasing IL-10 concentrations, and producing remission periods longer than six months. HMB and levamisole were also effective in lowering CIBDAI scores, but the abatement of clinical symptoms was slower and less pronounced in comparison with β-1,3/1,6-D-glucan. The results indicate that β-1,3/1,6-D-glucan can be useful in the treatment of canine IBD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23921342/